Already Registered? Log In Now Not Registered?
Complete this form to enter the webcast. Already Registered?

(* indicates required field)

Complete this form to enter the webcast.
(* indicates required field)



*Denotes required.


This event is now available on demand!

UpTempoSM Antibody: A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic

Event Overview:

Speed to clinic is a top priority for the majority of biopharmaceutical companies. Harmonizing technological innovation with platform biomanufacturing development and knowledge can address the time and cost barriers for protein biologics while producing stable, high-expressing antibody-based therapeutics. Catalent’s UpTempoSM  Antibody platform process combines industry-leading GPEx® cell line development technology with streamlined, phase-appropriate drug substance development to deliver products from early-stage development through GMP manufacturing. In addition, UpTempoSM  Antibody provides a flexible platform process for multi-chain expression and scalable manufacturing with consistent performance and product quality – all key aspects to deliver biotherapeutics on an expedited timeline for clinical trials.

Key Learning Objectives:
  • How UpTempoSM Antibody addresses key challenges bringing antibody therapeutic programs to clinical trials
  • What innovative technology and phase-appropriate, scalable bioprocessing developments are applied from gene to GMP batch release
  • How to deliver high-expressing, consistent antibody therapeutics on expeditious timelines for clinical studies
Who Should Attend:
  • Chief scientific officers
  • Process development scientists
  • CMC engineers
  • Bioprocessing engineers
  • Upstream development scientists
  • CEOs, VPs and Consultants of biologic development
  • VPs of bioprocessing
  • VPs of process development
  • VPs of biomanufacturing
  • Directors of biologic development, bioprocessing, process development and biomanufacturing
  • VPs and Directors of bioproduction
  • Directors of biologics


Featured Speaker's 


Laura Daley, PhD
Laura Daley, PhD
Senior Director, Molecular & Cellular Biology
Catalent Biologics


Dr Laura Daley is a Senior Director at Catalent Pharma Solutions, for which she supports Cell Line Development, R&D, and Cell and Molecular Biology activities. Laura received her PhD in Pharmacology and Physiology from Saint Louis University School of Medicine. She has over 16 years of industry experience in stem cell biology and gene editing, and continues to leverage her expertise in developing innovative platforms for protein manufacturing at Catalent.

Speaker's Email: laura.daley@catalent.com 


Tyler Gadoury
Tyler Gadoury
Senior Director, Process Development
Catalent Biologics


Tyler Gadoury currently serves as Senior Director of Process and Analytical Development at Catalent Pharma Solutions. He has over a decade of clinical and commercial biologics drug substance experience across numerous modalities, working with companies all over the world. Tyler holds a BS in Chemical Engineering, an MBA, and is a certified Lean Six Sigma Black Belt.

Speaker's Email: 
tyler.gadoury@catalent.com  




For any technical questions please contact Kristina Dunphey:
Kdunphey@mjhevents.com